Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDDiaMedica Therapeutics Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.16 | -$0.16 | -$0.16 |
| Q2 2024 | 1 | -$0.16 | -$0.16 | -$0.16 |
| Q3 2024 | 3 | -$0.18 | -$0.16 | -$0.17 |
| Q1 2025 | 1 | -$0.20 | -$0.20 | -$0.20 |
| Q2 2025 | 1 | -$0.21 | -$0.21 | -$0.21 |
| Q3 2025 | 1 | -$0.24 | -$0.24 | -$0.24 |
| Q4 2025 | 1 | -$0.23 | -$0.23 | -$0.23 |
| Q1 2026 | 1 | -$0.19 | -$0.19 | -$0.19 |
| Q2 2026 | 1 | -$0.19 | -$0.19 | -$0.19 |
| Q3 2026 | 1 | -$0.19 | -$0.19 | -$0.19 |
| Q4 2026 | 1 | -$0.19 | -$0.19 | -$0.19 |
DiaMedica Therapeutics Inc. Earnings Date And Information
DiaMedica Therapeutics Inc. last posted its earnings results on Wednesday, August 7th, 2024. The company reported $-0.13 earnings per share for the quarter, topping analysts' consensus estimates of $-0.16 by $0.03. The company had revenue of 0 for the quarter and had revenue of 0 for the year. DiaMedica Therapeutics Inc. has generated $-1 earnings per share over the last year ($-0.6 diluted earnings per share) and currently has a price-to-earnings ratio of -10.36. DiaMedica Therapeutics Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 17th, 2025 based on prior year's report dates.
DiaMedica Therapeutics Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/13/2024 | Q3 2024 | -$0.15 | $0 | $0 | ||
| 08/07/2024 | Q2 2024 | -$0.16 | -$0.13 | 0.03 | $0 | $0 |
| 05/08/2024 | Q1 2024 | -$0.16 | -$0.14 | 0.02 | $0 | |
| 03/19/2024 | Q4 2023 | -$0.14 | -$0.14 | 0 | $30.84 M | |
| 11/13/2023 | Q3 2023 | -$0.14 | -$0.12 | 0.02 | $0 | |
| 08/14/2023 | Q2 2023 | -$0.22 | -$0.16 | 0.06 | $0 | |
| 05/15/2023 | Q1 2023 | -$0.16 | -$0.20 | -0.04 | $0 | |
| 03/28/2023 | Q4 2022 | -$0.14 | -$0.14 | 0 | $0 | |
| 11/09/2022 | Q3 2022 | -$0.13 | -$0.12 | 0.01 | $76,000 | |
| 08/10/2022 | Q2 2022 | -$0.13 | $13,000 | |||
| 05/04/2022 | Q1 2022 | -$0.20 | -$0.13 | 0.07 | $0 | |
| 03/14/2022 | Q4 2021 | -$0.16 | -$0.17 | -0.01 | $0 | |
| 11/10/2021 | Q3 2021 | -$0.23 | -$0.18 | 0.05 | $0 | |
| 08/11/2021 | Q2 2021 | -$0.19 | -$0.17 | 0.02 | $0 | |
| 05/05/2021 | Q1 2021 | -$0.23 | -$0.19 | 0.04 | $0 | |
| 03/10/2021 | Q4 2020 | -$0.18 | -$0.25 | -0.07 | $0 | |
| 11/04/2020 | Q3 2020 | -$0.15 | -$0.19 | -0.04 | $0 | |
| 08/11/2020 | Q2 2020 | -$0.15 | -$0.17 | -0.02 | $0 | |
| 05/13/2020 | Q1 2020 | -$0.28 | -$0.19 | 0.09 | $0 | |
| 03/23/2020 | Q4 2019 | -$0.25 | -$0.19 | 0.06 | $0 |
DiaMedica Therapeutics Inc. Earnings: FAQ's
When is DiaMedica Therapeutics Inc.'s earnings date?
DiaMedica Therapeutics Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 17th, 2025 based off last year's report dates.
Did DiaMedica Therapeutics Inc. beat their earnings estimates last
quarter?
In the previous quarter, DiaMedica Therapeutics Inc. (:DMAC) reported $-0.13 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.16 by $0.03.
How can I listen to DiaMedica Therapeutics Inc.'s earnings conference
call?
The conference call for DiaMedica Therapeutics Inc.'s latest earnings report can be listened to online.
How can I read DiaMedica Therapeutics Inc.'s conference call transcript?
The conference call transcript for DiaMedica Therapeutics Inc.'s latest earnings report can be read online.
How much profit does DiaMedica Therapeutics Inc. generate each year?
DiaMedica Therapeutics Inc. (:DMAC) has a recorded net income of $0. DiaMedica Therapeutics Inc. has generated $-0.6 earnings per share over the last four quarters.
What is DiaMedica Therapeutics Inc.'s price-to-earnings ratio?
DiaMedica Therapeutics Inc. (:DMAC) has a price-to-earnings ratio of -10.36 and price/earnings-to-growth ratio is 1.83.